In the last decade, immunotherapy led to a paradigm shift in the treatment of numerous
malignancies. Alongside with monoclonal antibodies blocking programmed cell death …

Two decades of clinical cancer research with dendritic cell (DC)-based vaccination have
proved that this type of personalized medicine is safe and has the capacity to improve …

Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1 or CD279)
have noticeably improved the treatment landscape of advanced cancer patients. Nivolumab …

Cancer immunotherapy is experiencing a renaissance spearheaded by immune checkpoint
inhibitors (ICIs). This has spurred interest in 'upgrading'existing immunotherapies that …

The development of immune checkpoint inhibitors has altered the landscape of treatment of
advanced cancers. These drugs are well tolerated and have shown clinical activity against a …

Cancer immunotherapy is currently the hottest topic in the oncology field, owing
predominantly to the discovery of immune checkpoint blockers. These promising antibodies …

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over
the past two decades. Typically DC-based cancer immunotherapy entails loading patient …

After decades of setbacks, cancer immunology is living its Golden Age. Recent advances in
cancer immunology have provided new therapeutic approaches to treat cancer. The …

These are exciting times for cancer immunotherapy. After many years of disappointing
results, the tide has finally changed and immunotherapy has become a clinically validated …

Simple Summary Cancer immunotherapy has now attracted much attention because of the
recent success of immune checkpoint inhibitors. However, they are only beneficial in a …